PMID- 21466613
OWN - NLM
STAT- MEDLINE
DCOM- 20110826
LR  - 20111117
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 102
IP  - 7
DP  - 2011 Jul
TI  - Mismatched human leukocyte antigen class II-restricted CD8(+) cytotoxic T cells may 
      mediate selective graft-versus-leukemia effects following allogeneic 
      hematopoietic cell transplantation.
PG  - 1281-6
LID - 10.1111/j.1349-7006.2011.01949.x [doi]
AB  - Partial human leukocyte antigen (HLA)-mismatched hematopoietic stem cell 
      transplantation (HSCT) is often performed when an HLA-matched donor is not 
      available. In these cases, CD8(+) or CD4(+) T cell responses are induced 
      depending on the mismatched HLA class I or II allele(s). Herein, we report on an 
      HLA-DRB1*08:03-restricted CD8(+) CTL clone, named CTL-1H8, isolated from a 
      patient following an HLA-DR-mismatched HSCT from his brother. Lysis of a patient 
      Epstein-Barr virus-transformed B cell line (B-LCL) by CTL-1H8 was inhibited after 
      the addition of blocking antibodies against HLA-DR and CD8, whereas antibodies 
      against pan-HLA class I or CD4 had no effect. The 1H8-CTL clone did not lyse the 
      recipient dermal fibroblasts whose HLA-DRB1*08:03 expression was upregulated 
      after 1 week cytokine treatment. Engraftment of HLA-DRB1*08:03-positive primary 
      leukemic stem cells in non-obese diabetic/severe combined immunodeficient/gammac-null 
      (NOG) mice was completely inhibited by the in vitro preincubation of cells with 
      CTL-1H8, suggesting that HLA-DRB1*08:03 is expressed on leukemic stem cells. 
      Finally, analysis of the precursor frequency of CD8(+) CTL specific for recipient 
      antigens in post-HSCT peripheral blood T cells revealed a significant fraction of 
      the total donor CTL responses towards the individual mismatched HLA-DR antigen in 
      two patients. These findings underscore unexpectedly significant CD8 T cell 
      responses in the context of HLA class II.
CI  - (c) 2011 Japanese Cancer Association.
FAU - Hirosawa, Tomoya
AU  - Hirosawa T
AD  - Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
FAU - Torikai, Hiroki
AU  - Torikai H
FAU - Yanagisawa, Mayumi
AU  - Yanagisawa M
FAU - Kamei, Michi
AU  - Kamei M
FAU - Imahashi, Nobuhiko
AU  - Imahashi N
FAU - Demachi-Okamura, Ayako
AU  - Demachi-Okamura A
FAU - Tanimoto, Miyoko
AU  - Tanimoto M
FAU - Shiraishi, Keiko
AU  - Shiraishi K
FAU - Ito, Mamoru
AU  - Ito M
FAU - Miyamura, Koichi
AU  - Miyamura K
FAU - Shibata, Kiyosumi
AU  - Shibata K
FAU - Kikkawa, Fumitaka
AU  - Kikkawa F
FAU - Morishima, Yasuo
AU  - Morishima Y
FAU - Takahashi, Toshitada
AU  - Takahashi T
FAU - Emi, Nobuhiko
AU  - Emi N
FAU - Kuzushima, Kiyotaka
AU  - Kuzushima K
FAU - Akatsuka, Yoshiki
AU  - Akatsuka Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110509
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (HLA-D Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DR Serological Subtypes)
RN  - 0 (HLA-DR8 antigen)
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Graft vs Host Disease/etiology
MH  - Graft vs Leukemia Effect/*immunology
MH  - HLA-D Antigens/*immunology
MH  - HLA-DR Antigens/immunology
MH  - HLA-DR Serological Subtypes
MH  - HLA-DRB1 Chains
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Mice
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology/surgery
MH  - Transplantation, Homologous
EDAT- 2011/04/07 06:00
MHDA- 2011/08/30 06:00
CRDT- 2011/04/07 06:00
PHST- 2011/04/07 06:00 [entrez]
PHST- 2011/04/07 06:00 [pubmed]
PHST- 2011/08/30 06:00 [medline]
AID - 10.1111/j.1349-7006.2011.01949.x [doi]
PST - ppublish
SO  - Cancer Sci. 2011 Jul;102(7):1281-6. doi: 10.1111/j.1349-7006.2011.01949.x. Epub 
      2011 May 9.